Mega mergers, state-of-the-art stem cell facility and humorous pharmaceutical ads… What’s new for pharma in business?
Stephanie Sutton | | Quick Read
Mergers & Acquisitions
Bristol-Myers Squibb is acquiring Celgene in a stock and cash deal worth $74 billion. The combined company could become the fourth largest pharma firm in the US, but the deal still needs approval from shareholders and regulators.
Eli Lilly is buying Loxo Oncology for $8 billion, which is around $235 per share. Loxo is working on cancer treatments based on the genetic markers of tumors and their portfolio includes the FDA-approved TRK inhibitor, Vitrakvi.
Enjoy our FREE content!
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Login if you already created an account
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine